# OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)

> **NCT07576257** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sahlgrenska University Hospital** · enrollment: 110 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** potassium binder

## Key facts

- **NCT ID:** NCT07576257
- **Lead sponsor:** Sahlgrenska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-06-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07576257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07576257, "OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07576257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*